GlaxoSmithKline PLC (LON:GSK) Stock “Reduce” Rating Reconfirmed at Kepler Cheuvreux; The Target Price is GBX 1340.00; Last Week Endeavour Silver Corp. (EXK) Coverage

In an analyst report released on Thursday morning, GlaxoSmithKline PLC (LON:GSK) stock had its “Reduce” Rating reaffirmed by professional analysts at Kepler Cheuvreux. They currently have a GBX 1340.00 TP on firm. Kepler Cheuvreux’s target gives a potential upside of 1.57% from the company’s close price.

Among 8 analysts covering Endeavour Silver Corp (NYSE:EXK), 3 have Buy rating, 1 Sell and 4 Hold. Therefore 38% are positive. Endeavour Silver Corp had 29 analyst reports since August 24, 2015 according to SRatingsIntel. The stock of Endeavour Silver Corp. (NYSE:EXK) earned “Buy” rating by H.C. Wainwright on Wednesday, October 11. The stock of Endeavour Silver Corp. (NYSE:EXK) has “Buy” rating given on Thursday, January 11 by Noble Financial. H.C. Wainwright maintained Endeavour Silver Corp. (NYSE:EXK) on Friday, July 14 with “Buy” rating. The rating was downgraded by IBC on Tuesday, February 23 to “Underperformer”. The firm has “Buy” rating by H.C. Wainwright given on Friday, August 4. The stock of Endeavour Silver Corp. (NYSE:EXK) has “Buy” rating given on Friday, August 4 by Noble Financial. BMO Capital Markets upgraded Endeavour Silver Corp. (NYSE:EXK) on Tuesday, April 4 to “Market Perform” rating. As per Monday, June 27, the company rating was upgraded by Raymond James. As per Monday, January 9, the company rating was downgraded by Canaccord Genuity. The firm has “Buy” rating by Noble Financial given on Wednesday, June 7. See Endeavour Silver Corp. (NYSE:EXK) latest ratings:

26/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $6.0 Maintain
11/01/2018 Broker: Noble Financial Rating: Buy Maintain
11/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $6.0 Maintain
17/11/2017 Broker: BMO Capital Markets Rating: Market Perform Initiate
16/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $6.0 Maintain
03/11/2017 Broker: Noble Financial Rating: Buy Maintain
03/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $6.0 Maintain
25/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $6.0 Maintain
11/10/2017 Broker: Noble Financial Rating: Buy Maintain
11/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $6.0 Maintain

Endeavour Silver Corp., a mid-tier precious metals mining company, engages in evaluation, acquisition, exploration, development, extraction, processing, refining, and reclamation of silver mining properties in Mexico and Chile. The company has market cap of $273.48 million. The firm also explores for gold deposits. It has a 438 P/E ratio. It holds interest in the Guanaceví mine in the Durango state; and the Bolañitos and El Cubo mines in the Guanajuato state of Mexico.

The stock decreased 2.67% or $0.06 during the last trading session, reaching $2.19. About 1.26M shares traded. Endeavour Silver Corp. (NYSE:EXK) has declined 7.14% since February 8, 2017 and is downtrending. It has underperformed by 23.84% the S&P500.

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company has market cap of 64.57 billion GBP. It operates through four divisions: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. It has a 27.89 P/E ratio. The firm offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV.

The stock increased 2.61% or GBX 33.6 during the last trading session, reaching GBX 1319. About 3.62 million shares traded. GlaxoSmithKline plc (LON:GSK) has 0.00% since February 8, 2017 and is . It has underperformed by 16.70% the S&P500.

Analysts await GlaxoSmithKline plc (LON:GSK) to report earnings on February, 14. They expect $0.64 EPS, down 1.54% or $0.01 from last year’s $0.65 per share. GSK’s profit will be $31.33 million for 515.23 P/E if the $0.64 EPS becomes a reality. After $0.85 actual EPS reported by GlaxoSmithKline plc for the previous quarter, Wall Street now forecasts -24.71% negative EPS growth.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: